NPCE Stock Price, NeuroPace, Inc. Quote, Chart

Market Summary

USD13.56-0.45

Market Closed

-3.21%

NPCE Alerts

1 major insider sales recently.

NPCE Stock Price

View Fullscreen

NPCE RSI Chart

NPCE Valuation

Market Cap

384.4M

Price/Earnings (Trailing)

-11.66

Price/Sales (Trailing)

5.88

Price/Free Cashflow

-19.34

NPCE Price/Sales (Trailing)

NPCE Profitability

Return on Equity

-159.56%

Return on Assets

-30.61%

Free Cashflow Yield

-5.17%

NPCE Fundamentals

NPCE Revenue

Revenue (TTM)

65.4M

Rev. Growth (Yr)

40.84%

Rev. Growth (Qtr)

9.65%

NPCE Earnings

Earnings (TTM)

-33.0M

Earnings Growth (Yr)

44.37%

Earnings Growth (Qtr)

14.57%

Breaking Down NPCE Revenue

Last 7 days

-1.4%

Last 30 days

4.1%

Last 90 days

-7.0%

Trailing 12 Months

205.4%

How does NPCE drawdown profile look like?

NPCE Financial Health

Current Ratio

5.71

Debt/Equity

2.76

Debt/Cashflow

-0.35

NPCE Investor Care

Shares Dilution (1Y)

5.54%

Diluted EPS (TTM)

-1.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	48.6M	54.9M	60.2M	65.4M
2022	45.3M	42.9M	43.7M	45.5M
2021	42.4M	47.4M	44.9M	45.2M
2020	0	0	0	41.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of NeuroPace, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 23, 2024	orbimed advisors llc	sold	-311,393	14.29	-21,791	-
Apr 22, 2024	orbimed advisors llc	sold	-345,756	14.05	-24,609	-
Apr 19, 2024	orbimed advisors llc	sold	-255,907	14.02	-18,253	-
Apr 18, 2024	orbimed advisors llc	sold	-36,879	14.06	-2,623	-
Apr 17, 2024	orbimed advisors llc	sold	-4,245	14.15	-300	-
Apr 16, 2024	orbimed advisors llc	sold	-197,107	14.01	-14,069	-
Apr 12, 2024	orbimed advisors llc	sold	-333,116	14.42	-23,101	-
Apr 11, 2024	orbimed advisors llc	sold	-6,692,920	14.49	-461,899	-
Feb 27, 2024	morrell martha	acquired	-	-	12,500	chief medical officer
Feb 27, 2024	kuhn rebecca	acquired	-	-	12,500	chief financial officer

Which funds bought or sold NPCE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 05, 2024	CWM, LLC	new	-	2,000	2,000	-%
Mar 11, 2024	VANGUARD GROUP INC	added	7.00	502,516	4,259,120	-%
Feb 26, 2024	Virtu Financial LLC	new	-	111,000	111,000	0.01%
Feb 15, 2024	BARCLAYS PLC	added	28.9	39,000	144,000	-%
Feb 15, 2024	TOWNSQUARE CAPITAL LLC	new	-	163,505	163,505	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	379,635	379,635	-%
Feb 15, 2024	Nantahala Capital Management, LLC	added	92.42	12,331,400	24,201,200	0.72%
Feb 14, 2024	LAZARD ASSET MANAGEMENT LLC	new	-	40,000	40,000	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-43.55	-234,758	349,509	0.01%
Feb 14, 2024	Balyasny Asset Management L.P.	new	-	279,978	279,978	-%

Are Funds Buying or Selling NPCE?

Are funds buying NPCE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NPCE

No. of Funds

NPCE Alerts

1 major insider sales recently.

Unveiling NeuroPace, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	orbimed advisors llc	15.2%	4,003,967	SC 13G/A
Feb 14, 2024	kck ltd.	21.3%	5,593,773	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	morgan stanley	9.4%	2,460,716	SC 13G/A
Feb 02, 2024	soleus private equity fund i, l.p.	2.2%	582,186	SC 13G/A
Feb 14, 2023	orbimed advisors llc	16.1%	4,012,281	SC 13G/A
Feb 14, 2023	soleus private equity fund i, l.p.	2.4%	592,186	SC 13G/A
Feb 10, 2023	morgan stanley	8.8%	2,188,593	SC 13G
Feb 09, 2023	fmr llc	-	0	SC 13G
Nov 23, 2022	accelmed partners ii l.p.	17.8%	4,432,948	SC 13D/A

Recent SEC filings of NeuroPace, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	4	Insider Trading
Apr 22, 2024	ARS	ARS
Apr 22, 2024	DEF 14A	DEF 14A
Apr 22, 2024	DEFA14A	DEFA14A
Apr 18, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Mar 15, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	10-K	Annual Report
Mar 05, 2024	8-K	Current Report
Mar 05, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to NeuroPace, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-2.82%	-2.78%	32.41	4.63	-8.12%	-17.45%
BDX	67.5B	19.5B	-3.26%	-10.41%	53.77	3.46	4.02%	-22.04%
ALGN	23.6B	3.9B	-1.72%	-10.74%	52.95	6.1	3.42%	23.09%
BAX	20.8B	14.8B	-2.03%	-9.90%	7.83	1.4	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	0.44%	-12.46%	22.62	0.76	-2.44%	-22.68%
ATR	9.2B	3.5B	-2.07%	18.57%	32.49	2.65	4.97%	18.89%
BIO	8.1B	2.7B	-18.49%	-36.41%	-12.74	3.04	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.85%	-24.53%	-47.67	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-3.04%	14.62%	-560.04	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-3.54%	-1.62%	12.12	0.36	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-13.37%	-14.88%	-1.92	0.41	7.73%	-1066.14%
ANIK	384.6M	166.7M	3.23%	-3.00%	-4.65	2.31	6.67%	-456.34%
ANGO	235.1M	324.0M	11.39%	-31.43%	-1.22	0.73	-3.19%	-337.41%
APYX	52.0M	52.3M	18.11%	-48.10%	-2.78	0.99	17.61%	19.28%
AEMD	4.0M	3.7M	-12.07%	240.00%	-0.33	1.07	5.77%	8.23%

NeuroPace, Inc. News

Latest updates

NeuroPace, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	9.6%	18.00	16.00	17.00	14.00	13.00	11.00	10.00	11.00	11.00	10.00	13.00	11.00	11.00	13.00	8.00	10.00
Gross Profit	10.7%	14.00	12.00	12.00	10.00	9.00	8.00	7.00	8.00	8.00	8.00	9.00	8.00	8.00	10.00	5.00	7.00
Operating Expenses	2.3%	19.00	18.00	20.00	19.00	19.00	18.00	18.00	18.00	17.00	14.00	14.00	12.00	11.00	11.00	9.00	13.00
S&GA Expenses	-1.3%	13.00	13.00	14.00	13.00	14.00	13.00	13.00	12.00	12.00	9.00	10.00	8.00	7.00	7.00	6.00	8.00
R&D Expenses	12.1%	5.00	5.00	5.00	5.00	5.00	6.00	6.00	6.00	5.00	4.00	4.00	4.00	4.00	4.00	3.00	5.00
Interest Expenses	2.1%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	4.00	3.00
Net Income	14.6%	-6.20	-7.26	-9.12	-10.37	-11.15	-11.78	-12.69	-11.46	-10.69	-8.08	-8.49	-8.81	-4.62	-4.13	-8.79	-6.74
Net Income Margin	20.0%	-0.50*	-0.63*	-0.77*	-0.95*	-1.03*	-1.07*	-1.00*	-0.85*	-0.80*	-0.67*	-0.55*	-0.62*	-	-	-	-
Free Cashflow	-48.7%	-3.37	-2.27	-4.40	-9.83	-7.98	-7.01	-10.82	-11.70	-8.36	-4.55	-6.12	-5.93	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	8.4%	108	99.00	102	106	114	120	119	129	134	141	147	50.00	56.00
Current Assets	10.4%	93.00	84.00	87.00	90.00	98.00	104	112	122	133	140	146	47.00	55.00
Cash Equivalents	85.8%	18.00	10.00	8.00	7.00	7.00	6.00	6.00	7.00	19.00	27.00	31.00	14.00	27.00
Inventory	14.9%	11.00	10.00	10.00	11.00	10.00	9.00	8.00	8.00	8.00	7.00	7.00	7.00	7.00
Net PPE	5.7%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	1.00
Liabilities	4.9%	87.00	83.00	81.00	79.00	79.00	77.00	66.00	66.00	60.00	60.00	58.00	65.00	62.00
Current Liabilities	26.6%	16.00	13.00	12.00	10.00	11.00	9.00	11.00	12.00	9.00	9.00	8.00	11.00	10.00
Long Term Debt	1.9%	57.00	56.00	55.00	54.00	53.00	52.00	51.00	50.00	50.00	50.00	49.00	50.00	51.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	4.00	2.00
LT Debt, Non Current	1.9%	57.00	56.00	55.00	54.00	53.00	52.00	51.00	50.00	50.00	50.00	49.00	50.00	51.00
Shareholder's Equity	26.2%	21.00	16.00	21.00	27.00	35.00	43.00	53.00	63.00	74.00	82.00	89.00	-	-
Retained Earnings	-1.2%	-503	-497	-490	-481	-470	-459	-447	-435	-423	-413	-405	-396	-387
Additional Paid-In Capital	2.0%	524	514	512	509	507	504	502	499	498	495	494	240	240
Shares Outstanding	6.0%	28.00	26.00	26.00	25.00	25.00	25.00	25.00	24.00	24.00	24.00	18.00	-	-
Float	-	-	-	66.00	-	-	-	50.00	-	-	-	198	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-47.8%	-3,341	-2,260	-4,402	-9,698	-7,900	-6,900	-10,700	-11,400	-8,200	-4,450	-6,050	-5,900	-6,400	-5,400	-3,300	-6,500
Share Based Compensation	-2.6%	2,357	2,421	2,655	2,125	2,076	2,182	2,603	1,488	1,876	1,107	1,103	202	487	301	290	301
Cashflow From Investing	-17.3%	3,468	4,191	5,300	10,068	8,898	6,969	8,236	-306	-154	-190	-80,017	-5,035	-10,046	-250	-	-471
Cashflow From Financing	30522.2%	8,214	-27.00	195	-255	-138	-8.00	635	1.00	911	-	103,193	-1,578	-279	38,815	3,953	12,520
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

NPCE Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 65,421	$ 45,520
Cost of goods sold	17,299	13,027
Gross profit	48,122	32,493
Operating expenses
Research and development	20,778	21,946
Selling, general and administrative	54,518	51,341
Total operating expenses	75,296	73,287
Loss from operations	(27,174)	(40,794)
Interest income	3,050	1,578
Interest expense	(8,517)	(7,529)
Other income (expense), net	(315)	(337)
Net loss	(32,956)	(47,082)
Unrealized loss on available-for-sale debt securities	0	(836)
Comprehensive loss	$ (32,956)	$ (47,918)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (1.27)	$ (1.91)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (1.27)	$ (1.91)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)	25,851,813	24,594,784
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	25,851,813	24,594,784

NPCE Balance Sheet

2023-12-31

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 18,058,000	$ 6,605,000
Short-term investments	48,396,000	70,804,000
Accounts receivable	12,314,000	7,482,000
Inventory	11,214,000	9,712,000
Prepaid expenses and other current assets	2,737,000	3,111,000
Total current assets	92,719,000	97,714,000
Property and equipment, net	1,003,000	1,064,000
Operating lease right-of-use asset	13,405,000	14,838,000
Restricted cash	122,000	122,000
Deferred offering costs	387,000	347,000
Other assets	15,000	21,000
Total assets	107,651,000	114,106,000
Current liabilities
Accounts payable	2,332,000	2,147,000
Accrued liabilities	11,180,000	7,414,000
Operating lease liability	1,627,000	1,415,000
Deferred revenue	1,090,000	0
Total current liabilities	16,229,000	10,976,000
Long-term debt	56,954,000	52,913,000
Operating lease liability, net of current portion	13,814,000	15,440,000
Total liabilities	86,997,000	79,329,000
Commitments and contingencies (Note 5)
Stockholders’ equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2023 and December 31, 2022	0	0
Common stock, $0.001 par value, 200,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 27,823,465 and 25,045,751 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	28,000	25,000
Additional paid-in-capital	524,435,000	506,713,000
Accumulated other comprehensive loss	0	(1,108,000)
Accumulated deficit	(503,809,000)	(470,853,000)
Total stockholders’ equity	20,654,000	34,777,000
Total liabilities and stockholders’ equity	$ 107,651,000	$ 114,106,000

About NeuroPace, Inc.

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

CEO	Mr. Joel D. Becker
WEBSITE	neuropace.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	169

NeuroPace, Inc. Frequently Asked Questions

What is the ticker symbol for NeuroPace, Inc.? What does NPCE stand for in stocks?

NPCE is the stock ticker symbol of NeuroPace, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NeuroPace, Inc. (NPCE)?

As of Wed Apr 24 2024, market cap of NeuroPace, Inc. is 384.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NPCE stock?

You can check NPCE's fair value in chart for subscribers.

What is the fair value of NPCE stock?

You can check NPCE's fair value in chart for subscribers. The fair value of NeuroPace, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of NeuroPace, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NPCE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is NeuroPace, Inc. a good stock to buy?

The fair value guage provides a quick view whether NPCE is over valued or under valued. Whether NeuroPace, Inc. is cheap or expensive depends on the assumptions which impact NeuroPace, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NPCE.

What is NeuroPace, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, NPCE's PE ratio (Price to Earnings) is -11.66 and Price to Sales (PS) ratio is 5.88. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NPCE PE ratio will change depending on the future growth rate expectations of investors.